Positive clinical data at a major medical congress (EHA) supports the fundamental thesis for both olverembatinib and lisaftoclax label expansion. Watch for FDA/EMA interactions on potential label updates for olverembatinib in CML second-line and Ph+ ALL. The chemotherapy-free pediatric combination is a novel data point that de-risks the pipeline. No near-term binary catalyst (e.g., PDUFA date or enrollment completion) announced in this filing.
Price Chart
Executive Summary
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, including data from its two core assets olverembatinib and lisaftoclax. Key highlights include statistically significant MMR rates vs. control in CML (54.3% vs 10.0% at 6 months, P<0.001), strong POLARIS-1 Ph+ ALL registrational Phase III results (94.4% CR/CRi, 93.1% MRD-negativity by cycle 9), and promising chemotherapy-free pediatric Ph+ ALL data (ORR 88.9%). The data support label expansion for olverembatinib into second-line CML without T315I and validate lisaftoclax's real-world utility in AML. No financial figures were disclosed.
Key Facts
- 17 clinical updates presented at EHA2026, including 8 posters
- Olverembatinib: 6-month MMR 54.3% vs 10.0% (P<0.001) in CML-CP patients who failed at least 2 prior TKIs
- Olverembatinib: CR/CRi 94.4%, MRD-negativity 93.1% by cycle 9 in Ph+ ALL (POLARIS-1 registrational Phase III)
- Lisaftoclax: real-world AML CR/CRi 72%, MRD-negativity 61% (N=25)
- Pediatric Ph+ ALL combination (olverembatinib + lisaftoclax): ORR 88.9%, MRD-negativity 66.7%
- Lisaftoclax in BTKi-refractory CLL/SLL: median PFS 23.9 months, ORR 62.5%
- Olverembatinib remains FDA- and EMA-cleared in three global registrational trials (POLARIS-1, 2, 3)
- Lisaftoclax has 4 ongoing global registrational Phase III trials (GLORA, GLORA-2, GLORA-3, GLORA-4)
Financial Impact
No financial figures disclosed in the filing. Clinical data supports potential label expansion for both core assets, which could materially expand the addressable market for olverembatinib into second-line CML and lisaftoclax into AML and pediatric ALL.
Risk Factors
- Both drugs have not yet received US FDA approval—approval risk remains
- China NRDL pricing pressure could limit commercial upside
- Competition from approved Bcl-2 inhibitors (venetoclax) and third-gen TKIs (asciminib) in global markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-068502 |
| Document: ea029473801ex99-2.htm | 0001213900-26-068502 |
| Document: ea0294738-6k_ascentage.htm | 0001213900-26-068502 |
| Document: 0001213900-26-068502-index-headers.html | 0001213900-26-068502 |
| Document: 0001213900-26-068502-index.html | 0001213900-26-068502 |
| Document: 0001213900-26-068502.txt | 0001213900-26-068502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.43 (+3.38%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.43 (+3.38%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.43 (+5.00%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.43 (−0.36%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.43 (+10.94%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.43 (−8.48%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.43 (−8.21%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.43 (−18.34%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.43 (−16.03%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.43 (−19.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers